News

  • Coming soon – a new protein biomarker panel for oncology

    A new 92-plex protein panel containing a combination of  established and exploratory markers focused on oncology will be available in December for shipment as kits, or via our Analysis Service. This panel will provide a perfect complement to our existing panel, Olink® ONCOLOGY II, enabling oncologi...
  • Olink wins major Frost & Sullivan award

    Frost & Sullivan has recognized Olink Proteomics with its 2018 Global Enabling Technology Leadership Award for the development of our multiplex cardiovascular disease (CVD) panels. Each year, Frost & Sullivan presents this award to a company that develops a pioneering technology that not onl...
  • New office and lab facilities for Olink’s US organization

    In the less than two and a half years since Olink Proteomics established a base for its US operations in Watertown MA, the size of the US organization and its customer-base have grown dramatically. To reflect and build on this level of success, the US organization has just moved into bigger, better ...
  • Protein biomarkers making an impact in clinical trials for Atopic Dermatitis.

    DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial. Protein data generated using Olink’s biomarker panels provided evidence of the favora...
  • Petter Brodin – in his own words

    A story from the Olink user community. Petter Brodin talks about his landmark study (Olin et al, 2018), published in Cell, “Stereotypic immune system development in newborn children“. BiographyPetter Brodin studied medicine at Karolinska Institutet an...
  • White paper on study design now available

    Strategies for design of protein biomarker studies”  is a new white paper that describes important aspects of study design to consider when planning your future research. These include a well-defined study objective, adequate sample size, control of confounding factors and...
  • Olink NEURO EXPLORATORY panel now available

    Olink is delighted to announce the  launch of a new biomarker panel that complements and expands on Olink’s ever-growing portfolio of high quality protein assays. With 91 of 92 assays in the new panel representing new additions to our library, this extends the power of the Olink platform for d...
  • Coming soon – a neuro exploratory biomarker panel

    A new 92-plex protein panel containing a combination of exploratory and established markers focused on neurology-related diseases and biological processes will be available for shipment as kits, or via our Analysis Service at the end of August.  Full information about this new panel and the assays i...
  • New white papers from Olink

      “Strategies for design of protein biomarker studies” This white paper describes important aspects of study design to consider when planning your future research. These include a well-defined study objective, adequate sample size, control of confounding factors a...
  • Olink Service Provider at SciLifeLab Stockholm

    Plasma Profiling national facility at Science for Life Laboratory in Stockholm Sweden certified as service provider Olink Proteomics is delighted that the Plasma Profiling national facility at Science for Life Laboratory in Stockholm, Sweden has been certified as a service provider for running Olink...